USA Archives

News and Trends 26 Aug 2022

Beyond Biotech podcast 11: Ilya Pharma, IRB Barcelona, Krystal Biotech, Phase Genomics

This week it’s another four interview podcast, and the introduction of a new feature. Our guests are Ilya Pharma CEO and co-founder Evelina Vågesjö and chief financial officer Oskar Lund; Miguel Martín-Álvarez, postdoctoral fellow in the cancer science unit at IRB Barcelona; Hubert Chen, head of clinical development at Krystal Biotech; and Ivan Liachko, CEO […]

August 26, 2022

News and Trends 26 Aug 2022

Cholesterol targeting antibodies produced by Bio-Rad Laboratories

Antibodies that target a protein playing a key role in the regulation of cholesterol levels have been introduced by Bio-Rad Laboratories. The range of type 1 antibodies inhibit the binding of evolocumab (Repatha) to its target – human proprotein convertase subtilisin/kevin type 9 (PCSK9). Recombinant antibodies These sequence-defined, recombinant antibodies are suitable for developing highly […]

August 26, 2022 - 2 minutesmins - By Liza Laws

News and Trends 26 Aug 2022

Ordaōs raises $5M to accelerate drug design and discovery

U.S. biotech company Ordaōs has raised $5 million in seed financing to aid in new product development and expand partner acquisition efforts. The oversubscribed round was led by Middleland Capital’s VTC Ventures with additional investments from Route 66 Ventures, Banyan Pacific Capital, IAG Capital Partners, and Citta Capital. Ordaōs is a drug design company that […]

August 26, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 25 Aug 2022

Hope for children with chronic graft versus host disease as Johnson & Johnson drug approved

A treatment for chronic graft versus host disease in children aged one year and older has been approved by the U.S. Food and Drug Administration (FDA). Graft versus host disease is a common complication after receiving a donor stem-cell or bone marrow transplantation. Sometimes, the graft doesn’t recognize the host as being friendly and sees the […]

August 25, 2022 - 3 minutesmins - By Liza Laws

News and Trends 25 Aug 2022

3T Biosciences launches with $40M financing

3T Biosciences wants to change the future of treatment for solid tumors and other immune-mediated diseases. And it exited from stealth today backed by $40 million in series A financing led by Westlake Village BioPartners with participation from Lightspeed Venture Partners. Proceeds from the financing will be used to help accelerate 3T Biosciences from a […]

August 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 24 Aug 2022

Hera Biotech bags $1.9M for endometriosis diagnostic test

San Antonio-based medical device start-up Hera Biotech has closed an oversubscribed $1.9 million seed financing round to support its commercialization strategy for its non-surgical diagnostic test for endometriosis, MetriDx. The funds will be used to complete an in-patient human clinical study, expand Hera’s IP portfolio, and support a regulatory pathway with the U.S. FDA. Investors […]

August 24, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 24 Aug 2022

BioAge partners with Age Labs to study healthy life length

BioAge Labs, Inc., a biotech company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, has partnered with Age Labs AS, a diagnostic company that develops tests for the early detection of age-related diseases. Under the terms of the agreement, BioAge will perform multi-omics analyses on samples and health records […]

August 24, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 24 Aug 2022

Oncolyze seeking investment for AML clinical trials

After successfully completing in vitro and in vivo experiments, which support the notion that its lead drug candidate OM-301 breaks down cancer cells and increases survival rates, Oncolyze now has its sights set on advancing OM-301 into clinical trials. Oncolyze has launched a Regulation A+ funding campaign to spread awareness of OM-301 among cancer patients, […]

August 24, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 24 Aug 2022

Amgen announces top-line results from biosimilar phase 3 study

Amgen has announced positive top-line results from its DAHLIA study. This was a randomized, double-blind, active-controlled, two-period crossover phase 3 study evaluating the efficacy and safety of ABP 959, a biosimilar candidate to SOLIRIS (eculizumab), compared with SOLIRIS in adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Amgen said the study met its primary endpoints, demonstrating […]

August 24, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

Freedom Biosciences exits stealth with $10.5M financing to develop mental health treatments

Freedom Biosciences, a U.S. clinical-stage biotech platform developing ketamine and psychedelic therapeutics, today emerged from stealth with $10.5 million in seed financing. MBX Capital led the round and was joined by PsyMed Ventures, Village Global and The Yale Startup, among others. The new financing will help the company advance its current lead ketamine program as […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

Cytimmune Sciences nanoparticles red recognizing entering and accumulating in cancer cells

News and Trends 23 Aug 2022

Novel nanotechnology ‘supercharges’ immune system molecules to fight cancer

Researchers from Cytimmune Sciences, a clinical-stage biotech company, have presented new data on the company’s novel cancer nanomedicines. The presentation took place at the Cytokine Drug Development Conference held in Boston, Massachusetts, late last month. David Oarr, Cytimmune’s president, participated in the event’s opening panel to discuss the current clinical status and future anticipated progress […]

August 23, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

Parkinson’s Foundation and Parkinson’s UK partner to drive drug development

The Parkinson’s Foundation and Parkinson’s UK, which funds research and provides support for people with Parkinson’s disease (PD), have announced a new international strategic partnership to boost investment in research on new treatments for PD, which affects 10 million people worldwide. Over the next three years, the Parkinson’s Foundation will invest a minimum of $3 […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

USA

Beyond Biotech podcast 11: Ilya Pharma, IRB Barcelona, Krystal Biotech, Phase Genomics

Cholesterol targeting antibodies produced by Bio-Rad Laboratories

Ordaōs raises $5M to accelerate drug design and discovery

Hope for children with chronic graft versus host disease as Johnson & Johnson drug approved

3T Biosciences launches with $40M financing

Hera Biotech bags $1.9M for endometriosis diagnostic test

BioAge partners with Age Labs to study healthy life length

Oncolyze seeking investment for AML clinical trials

Amgen announces top-line results from biosimilar phase 3 study

Freedom Biosciences exits stealth with $10.5M financing to develop mental health treatments

Novel nanotechnology ‘supercharges’ immune system molecules to fight cancer

Parkinson’s Foundation and Parkinson’s UK partner to drive drug development

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!